DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING THE ANTI-C5 CROVALIMAB ANTIBODY Russian patent published in 2024 - IPC A61K39/395 A61P7/00 

FIELD: medicine.

SUBSTANCE: disclosed is a method of treating or preventing a C5-related disease in a subject, said method being carried out by the following steps of administering: (i) intravenous administration of a loading dose of 1000 mg of anti-C5 antibody to a subject once; (ii) a subcutaneous loading dose of 340 mg of the anti-C5 antibody to subject 1 day after the start of the intravenous administration of the anti-C5 antibody; (iii) a subcutaneous loading dose of 340 mg of the anti-C5 antibody to subject 1 week, 2 weeks and 3 weeks after the start of the intravenous administration of the anti-C5 antibody once a week; (iv) subcutaneously administering a maintenance dose of 680 mg of the anti-C5 antibody to subject 4 weeks after the start of the intravenous administration of the anti-C5 antibody; and (v) repeating step (iv) several times with time intervals of 4 weeks, where said anti-C5 antibody is crovalimab, and said C5 disease is paroxysmal nocturnal haemoglobinuria (PNH).

EFFECT: invention provides long-term and coordinated blockade of terminal complement activity, sufficient reserve of free binding sites for the greater part of dosing interval, safety and therapeutic efficacy.

9 cl, 13 dwg, 1 tbl, 7 ex